文献速递围术期管理与 ERAS

颈动脉经颈动脉血运重建术后双联抗血小板替代方案与卒中和死亡风险增加相关

Dual Antiplatelet Alternatives are Associated With Increased Stroke and Death After Transcarotid Revascularization.
PubMed 文献 · Ann Surg · 2022-11-03

基于血管质量倡议(VQI)数据库2016年9月至2022年6月共29802例经颈动脉血运重建(TCAR)手术,其中82.7%维持双联抗血小板治疗(DAPT),17.3%使用替代方案。替代方案与院内死亡、同侧卒中、任何卒中及短暂性脑缺血发作风险增加相关,1年死亡率更高(4.7% vs 7.0%,P<0.01)。结论提示TCAR术后未维持DAPT者围术期及随访期卒中和死亡风险增加。

要点

  • TCAR术后使用双联抗血小板替代方案与院内卒中/死亡复合结局风险增加相关。
  • 替代方案组1年死亡率高于DAPT组(4.7% vs 7.0%,P<0.01)。
  • 外科医生需警惕并确保患者遵循推荐的双联抗血小板治疗。

核心结论

  • TCAR术后未维持DAPT的患者在围术期和随访期卒中和死亡风险增加。

研究设计与样本

  • 回顾性队列研究,纳入VQI数据库2016年9月至2022年6月共29802例TCAR手术,其中24651例(82.7%)维持DAPT,5151例(17.3%)使用替代方案。

主要发现

  • 单变量分析显示替代药物组院内死亡、同侧卒中、任何卒中及短暂性脑缺血发作发生率高于DAPT组。
  • 替代方案组1年死亡率高于DAPT组(4.7% vs 7.0%,P<0.01)。
  • 替代方案使用与院内卒中及院内卒中/死亡复合结局风险增加相关。
  • 替代方案使用与院内短暂性脑缺血发作、即刻支架闭塞及重返手术室风险增加显著相关。
  • 1年时两组卒中发生率无显著差异,但多变量调整后替代方案与1年死亡率升高相关。

临床怎么用

  • TCAR术后应确保患者遵循推荐的双联抗血小板治疗,避免不必要的替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the risks associated with the replacement of dual antiplatelets for alternate medication regimens. BACKGROUND: Patients undergoing transcarotid artery revascularization (TCAR) for atherosclerotic disease in the Vascular Quality Initiative database from September 2016 to June 2022 were included. In all, 29,802 TCAR procedures were captured between 2016 and 2022, consisting of 24,651 (82.7%) maintained on dual antiplatelet therapy (DAPT) and 5151 (17.3%) on alternative regimens. METHODS: Patients maintained on DAPT were compared with those on alternative regimens consisting of any combination of single antiplatelet monotherapy and/or anticoagulation. RESULTS: On univariable analysis, patients on alternative medications were more likely to experience in-hospital death, ipsilateral stroke, any stroke, and transient ischemic attacks compared with patients in the DAPT group. The mortality rate was higher at 1 year in the alternative cohort (4.7% vs 7.0%, P <0.01). The use of alternate medication regimens was associated with increased odds of stroke and the composite outcome of in-hospital stroke/death compared with DAPT. There was also a significant association between alternative medication use and increased odds of in-hospital transient ischemic attack, immediate stent occlusion, and return to the operating room. At 1 year, there was no significant difference in the incidence of stroke between the 2 groups. However, the use of alternate regimens was associated with higher 1-year of mortality after multivariable adjustment. CONCLUSIONS: Patients not maintained on DAPT after TCAR experienced an increased risk of stroke and death in the perioperative and follow-up periods. Increased surgeon vigilance is required to ensure compliance with dual antiplatelets as recommended.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Dakour-Aridi H, Motaganahalli RL, Fajardo A, et al. Dual Antiplatelet Alternatives are Associated With Increased Stroke and Death After Transcarotid Revascularization. Ann Surg. 2022. PMID: 36325904. doi:10.1097/SLA.0000000000005746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。